A record to read carefully

Liraglutide: evidence profile

Approved product · Randomized evidence

Status recorded · Page published

Read the product, route and approval scope together. A category label does not replace those details. Use the exercise to prepare questions, not to choose a treatment.

Evidence record

Product and route
Subcutaneous injection.
Approval scope
Saxenda: weight management for eligible patients.
Mechanism
Activates the GLP-1 receptor.
Evidence
Randomized trials.
Limits
Check other products separately.
Safety context
The label warns about severe gastrointestinal reactions.

Try this while reading

Before repeating a headline about liraglutide, find the participant count attached to the result itself. Put that count beside the number described at the beginning of the report. If they differ, look for an explanation in the participant flow, table notes or analysis description. Do not complete the explanation from the counts alone. Write a brief version of the headline that names the people whose records actually support it. Leave a visible question mark where their connection to the starting group remains unclear. You can then ask about that specific gap instead of treating everyone mentioned in the report as part of every calculation.

Questions to keep

  1. How many people's records support this particular result?
  2. Where does the report explain the difference between its starting count and this count?
  3. Who should be named in my version of the headline?

Sources to open

Checked dates belong to the linked records, rather than to this page's publication.

  1. SAXENDA — NLM; checked